BioEPâ„¢ - decision support that unlocks the full potential of EEG with mathematical modelling

BioEP uses the power of mathematical modelling to unlock the greater potential of EEG by increasing its diagnostic yield. BioEP analyses EEG for the presence of data features and brain network based markers that are shown to be elevated in people with epilepsy. BioEP is UKCA marked.

BioEP report displayed on a tablet

 

For more details on the mathematics behind BioEP or our scientific publications underpinning BioEP, take a look at our Impacts & Insights.

What is BioEPâ„¢ and how does it work?

BioEP analyses EEG data to determine if the analysis supports epilepsy or suggests a differential diagnosis.

Clinicians upload anonymised EEG data to the BioEP platform. In under 5 minutes, a BioEP report is generated.

Detects eight brain network-based features, shown in published research to be altered in people with epilepsy, which combine to form the BioEP biomarker.

Provides an additional layer of evidence to assist with diagnosis and decisions about the next steps. It can be applied in ‘live’ clinical practice and retrospectively to a backlog of inconclusive EEGs waiting for follow-up.

BioEPâ„¢ regulatory compliance

BioEP is a Class 1 Medical Device under 93/42/EEC Medical Device Directive (MDD) and is UKCA marked. Neuronostics are Cyber Essentials Plus certified and registered with ICO for data protection.

An overview of BioEPâ„¢ solutions

         Available in the UK                 Available Internationally 

In Development

BioEPâ„¢ for diagnosis

Designed to support clinicians in diagnosing epilepsy in adult seizure clinics, BioEP provides objective insights to enhance decision-making.

Additionally, BioEP for diagnosis can be applied retrospectively to existing EEG data, making it a valuable support tool for tackling backlog cases and prioritising patient care more efficiently.

BioEPâ„¢ for clinical trials

Designed to enhance the efficiency of clinical trials for new therapeutics by:​

  • Identifying optimal patient cohorts;​
  • Providing bespoke EEG analysis;​
  • Detecting patient subgroups most responsive to treatment.

 

BioEPâ„¢ for paediatrics

We have been contracted by Nottingham University Hospitals NHS Trust to develop and validate BioEP for children aged 2-18. Monitoring has been completed for our current OASIS trial which is assessing BioEP’s effectiveness in paediatric epilepsy diagnosis. Analysis is underway.

BioEPâ„¢ for prognosis

Early findings suggest that BioEP may assess the effectiveness of anti-seizure medication. Our current ECLIPSE trial is investigating its potential for treatment guidance and personalised epilepsy management.